4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)

✍ Scribed by G.G. Steger; R. Greil; R. Jakesz; A. Lang; B. Mlineritsch; E. Melbinger-Zeinitzer; C. Marth; H. Samonigg; E. Kubista; M. Gnant

• Book ID: 119600772
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 49 KB
• Volume: 7
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(09)72030-0